Aspirin use and prostate cancer mortality in men with high grade prostate cancer

Study identification

• EU PAS number:
  EUPAS3444
• Study ID:
  4877
• Official title and acronym:
  Aspirin use and prostate cancer mortality in men with high grade prostate cancer
• DARWIN EU® study:
  No
• Study countries:
  Ireland
• Study description:
  Observational studies have for many years reported associations between aspirin exposure and reduced incidence of many cancers including prostate cancer. More recently evidence has been building of an association between aspirin use and reduced mortality in both meta-analyses and observational studies. The biological mechanisms proposed are the anti-platelet activity of aspirin, which may impede the spread of metastases, and also through the inhibition of the cyclooxygenase 2 (COX-2) enzyme, expressed in response to tumour growth factors and inflammation. Studies have reported COX-2 to be expressed at higher levels in higher grade tumours, which are associated with poorer outcomes. In prostate cancer the associations between aspirin use and reduced mortality have been strongest in men with localised disease. This study aims to examine the associations between aspirin use and mortality in men diagnosed with high grade prostate tumours. The analysis will be stratified by tumour stage, to assess whether the association between aspirin use and prostate cancer mortality is modified according to whether the disease is localised or advanced.
• Study status:
  Finalised

Research institutions and networks

Institutions

Trinity College Dublin

Study timelines

Date when funding contract was signed

Actual:01/10/2010

Study start date

Actual:01/10/2011

Data analysis start date

Planned:01/02/2013

Date of final study report

Planned:30/09/2013

Actual:30/09/2013

Sources of funding

Non-for-profit organisation (e.g. charity)

More details on funding

Irish Cancer Society

Regulatory

• Was the study required by a regulatory body?:
  No